Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Industrial Estimate
Composite Estimate
500 Stocks Estimate
Gold
Crude Oil
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Merck & Co
(NY:
MRK
)
126.04
+0.26 (+0.21%)
Official Closing Price
Updated: 7:00 PM EDT, Jul 9, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
6,339,274
Open
125.24
Bid (Size)
125.35 (1)
Ask (Size)
127.37 (1)
Prev. Close
125.78
Today's Range
123.70 - 126.09
52wk Range
99.14 - 134.63
Shares Outstanding
2,531,374,696
Dividend Yield
2.32%
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Merk Animal Health Completes Acquisition of Elanco Animal Health Assets
Today 13:59 EDT
Merck Animal Health announced the purchase of Elanco Animal Health's aquaculture business.Merck & Company (NYSE:MRK) completed the acquisition of the aquaculture bus
Via
Benzinga
3 Undervalued Blue-Chip Stocks Ready for a Big Comeback
Today 9:08 EDT
Uncover top picks in undervalued blue-chip stocks, unfairly punished yet consistently delivering strong operational results
Via
InvestorPlace
Performance
YTD
+11.30%
+11.30%
1 Month
-4.14%
-4.14%
3 Month
-0.53%
-0.53%
6 Month
+6.43%
+6.43%
1 Year
+14.62%
+14.62%
More News
Read More
Merck Animal Health Completes Acquisition of Elanco’s Aqua Business
Today 8:30 EDT
From
Merck & Co., Inc.
Via
Business Wire
Healthcare Stocks Continue To Lag The Market-Can Anything Help ?
July 08, 2024
Via
Talk Markets
EXCLUSIVE: GLP-1 Weight-Loss Drugs Could Become A Trillion-Dollar Market, Predicts Tema ETFs CEO
July 07, 2024
Via
Benzinga
Topics
ETFs
Merck & Co Unusual Options Activity
July 05, 2024
Via
Benzinga
Insights Into Merck & Co's Performance Versus Peers In Pharmaceuticals Sector
July 02, 2024
Via
Benzinga
Roche's New Immunotherapy Fails To Show Benefit Over Merck's Blockbuster Keytruda In Lung Cancer Patients
July 05, 2024
Via
Benzinga
What The Quest For New Cholesterol Treatments Means For Novartis, Merck — And Patients
July 05, 2024
Via
Investor's Business Daily
Beat the CPI: 7 Blue-Chip Stocks Growing Faster Than Inflation
July 04, 2024
Via
InvestorPlace
mRNA Technology Promises To Make A Long-Time Coming Turning Point In Cancer Treatment
July 02, 2024
Via
Benzinga
Exposures
COVID-19
Market Whales and Their Recent Bets on MRK Options
July 01, 2024
Via
Benzinga
A Closer Look at Merck & Co's Options Market Dynamics
June 27, 2024
Via
Benzinga
5 Biggest Winners, 5 Biggest Losers From Dow Jones Industrial Average In First Half 2024
July 01, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
What's Going On With Merck Stock On Monday?
July 01, 2024
Via
Benzinga
Merck and Orion Announce Mutual Exercise of Option Providing Merck Global Exclusive Rights to Opevesostat, an Investigational CYP11A1 Inhibitor, for the Treatment of Metastatic Castration-Resistant Prostate Cancer
July 01, 2024
From
Merck & Co., Inc.
Via
Business Wire
Merck to Hold Second-Quarter 2024 Sales and Earnings Conference Call July 30
July 01, 2024
From
Merck & Co., Inc.
Via
Business Wire
3 Sectors That Could Get Slammed by Attempts to Reduce U.S. Debt
June 29, 2024
Via
InvestorPlace
7 Quiet Blue-Chip Stocks on the Verge of a Big Breakout Rally
June 28, 2024
Via
InvestorPlace
What's Going On With Merck Stock On Friday?
June 28, 2024
Via
Benzinga
Merck Receives Positive EU CHMP Opinion for WINREVAIR™ (sotatercept) in Pulmonary Arterial Hypertension (PAH)
June 28, 2024
From
Merck & Co., Inc
Via
Business Wire
CDC’S ACIP Unanimously Recommends Merck’s CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Pneumococcal Vaccination in Appropriate Adults
June 27, 2024
From
Merck & Co., Inc.
Via
Business Wire
Dow Jones Powerhouse Merck Dives On Surprise FDA Rejection
June 27, 2024
Via
Investor's Business Daily
Topics
Stocks
Exposures
Product Safety
US Equities
This Recent FDA Approval Is Bad News for Pfizer
June 27, 2024
Via
The Motley Fool
Exposures
Product Safety
FDA Declines To Approve Merck-Daiichi Sankyo Partnered Lung Cancer Drug
June 27, 2024
Via
Benzinga
Exposures
Product Safety
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.